ClinicalTrials.gg
WithdrawnNCT01429168RESPOND-EUROPEUpdated Feb 18, 2022

A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

A Phase 4 interventional study of Etoricoxib and Placebo for etoricoxib in Osteoarthritis, sponsored by Organon and Co. Withdrawn. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Osteoarthritis by Organon & Co. — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Organon & Co..

Enrollment
12th of 12
0 · median 508
Started
2011
the only one that year
Phase 4
2 of 15
none open now
Registered
11th of 15
by date

Among the 15 studies in Osteoarthritis by Organon & Co., this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 4, and was the 11th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies in Osteoarthritis by Organon & Co. is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Osteoarthritis by Organon & Co. as a file.
02

Study summary

This two-part study will evaluate the effectiveness of etoricoxib in controlling pain in participants with osteoarthritis who are experiencing inadequate response to their current treatments. In Part 1, all participants will receive open-label etoricoxib 60 mg daily. Those participants who experience a clinically meaningful response to etoricoxib 60 mg daily within two weeks will be eligible to enter the double-blind withdrawal period (Part II). Responders entering Part 2 will be randomized in a 1:1 ratio to receive either etoricoxib 60 mg or placebo.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of osteoarthritis of the knee or hip that requires treatment
  • American Rheumatism Association (ARA) functional Class I, II or III
  • Receiving a stable dose of a traditional non-steroidal anti-inflammatory drug (NSAID), a Cox-2 selective inhibitor (other than etoricoxib, e.g. celecoxib), opioid therapy or tramadol to treat their osteoarthritis-related pain for at least 2 weeks and willing to maintain treatment during baseline phase
  • Moderate to severe daily pain intensity on his or her current pain regimen
  • Excepting osteoarthritis, patient is judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests
  • Negative serum pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Has not experienced at least 3 consecutive days of daily pain intensity >4 on 10-point scale
  • Severe hepatic insufficiency
  • Advanced renal insufficiency
  • Presence of gastro-intestinal ulcer disease with active bleeding or history of the same within the past 6 months or a presence or history of inflammatory bowel disease
  • History of gastric, biliary (including gastric bypass surgery), or small intestinal surgery that results in clinical malabsorption
  • Receiving or will likely require treatment with ≥14 consecutive days or repeated courses of pharmacologic doses of
  • Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease including a history of stroke, myocardial infarction or , and recent revascularization procedures
  • Any other mentioned in the approved study drug European Union (EU) Summary of Product Characteristics (SmPC)
  • Therapy with glucosamine and/or chondroitin sulfate for \<6 months prior to study start.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part 1: All Enrolled Participants

    All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.

    Drug: Etoricoxib

  • Experimental
    Part 2: Etoricoxib

    Drug: Etoricoxib

  • Placebo comparator
    Part 2: Placebo

    Drug: Placebo for etoricoxib

Interventions

  • One 60-mg tablet orally daily

    Also known as: MK-0663

  • DrugPlacebo for etoricoxib

    One 60-mg tablet orally daily

06

What researchers measure

Primary outcomes

  1. Mean Time to Loss of Efficacy in the Double Blind Withdrawal Period (Part 2)

    Time frame: Week 3 to Week 7

Secondary outcomes

  1. Proportion of Participants who Achieve ≥30% Reduction in Pain During Part I

    Time frame: Week 1 to Week 3

  2. Change in Mean of Daily Pain Scores

    Time frame: Week 1 to Week 7

  3. Proportion of Participants Meeting Criteria for Loss of Efficacy in Part 2

    Time frame: Week 3 to Week 7

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2011
First posted
Sep 5, 2011
Start
Oct 2011
Primary completionEst.
Aug 2012
CompletionEst.
Aug 2012
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01429168
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 5, 2011
Start date
Oct 2011
Primary completion
Aug 2012 (estimated)
Completion
Aug 2012 (estimated)
Last update
Feb 18, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion